Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer.

ABSTRACT:

Objective

Boennuokang^® leuprorelin acetate microspheres show a certain efficacy in patients with prostate cancer, but its utilization as neoadjuvant therapy in patients with high-risk prostate cancer remains unclear. Hence, this real-world study investigated the efficacy and safety of Boennuokang^® leuprorelin acetate microspheres-based treatment as neoadjuvant therapy in patients with high-risk prostate cancer.

Methods

This retrospective study included 53 patients with high-risk prostate cancer who received Boennuokang^® leuprorelin acetate microspheres as neoadjuvant therapy and laparoscopic radical prostatectomy.

Results

The median prostate-specific antigen (PSA) was 34.1 ng/mL before neoadjuvant therapy and reduced to 0.8 ng/mL after

SUBMITTER: Fu C 

PROVIDER: S-EPMC11961931 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature